Ex-Bax­al­ta CEO Lud­wig Hantson gets the top job at a trou­bled Alex­ion

So Lud­wig Hantson will get his chance to run a biotech com­pa­ny af­ter all.

A lit­tle less than nine months af­ter Shire closed on its deal to buy Bax­al­ta, a new spin­out out of Bax­ter, for $32 bil­lion, the for­mer CEO at Bax­al­ta now has the top job at Alex­ion.

Hantson had run Bax­ter Bio­Science be­fore they gave him the reins at Bax­al­ta, giv­ing him a run at op­er­at­ing a $6 bil­lion group re­spon­si­ble for launch­ing 13 prod­ucts. Shire, though, leaped on the buy­out short­ly af­ter it was spun out. Now he’ll be step­ping in­to a va­can­cy cre­at­ed by a mar­ket­ing scan­dal that took down both the CEO and the CFO, who were en­tan­gled in a scheme to push ear­ly sales of Soliris in or­der to meet Wall Street’s rev­enue ex­pec­ta­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER